Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03608267
Other study ID # SRB_201804_011 -- P2018/336
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 6, 2018
Est. completion date March 3, 2020

Study information

Verified date June 2020
Source Erasme University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Surgery is currently the only effective treatment for morbid obesity and can be divided into restrictive surgeries (Lap Band and Sleeve gastrectomy), malabsorptive surgeries (Biliary pancreatic deviation and duodenal switch) or a combination of both (RYGBP).

This latter technique is the most common and most effective surgical procedure performed worldwide and has been processed to be an effective treatment of morbid obesity and its complications, achieving excess weight loss of 65 to 80 %; 1-2 years after surgery (1,2).

Morbidity after RYGB includes the candy cane syndrome or afferent loop syndrome. Candy cane Roux syndrome in patients who have undergone RYGB refers to an excessively long blind afferent Roux limb at the gastrojejunostomy causing postprandial pain often relieved by vomiting. It is believed that the blind afferent limb ("candy cane") acts as an obstructed loop when filled with food (often preferentially), and the distention of the loop causes pain until the food either spills into the Roux limb or is vomited back out (3).

Patients have been reported presenting as early as three months and as late as 11 years after their initial RYGB, typically with symptoms of postprandial epigastric pain, nausea, vomiting, and reflux or food regurgitation (4). The diagnosis is confirmed by upper gastrointestinal contrast studies or endoscopy. On upper gastrointestinal series, the afferent limb fills before contrast spills into the Roux limb. On upper endoscopy, the afferent limb is usually the most direct outlet of the gastrojejunostomy (3).

The treatment is revision bariatric surgery, most commonly laparoscopic resection of the afferent limb, which ranged in length from 3 to 22 cm in one study (mean of 7.6 cm) (3). Symptoms resolve after revision surgery in most patients. Surgeons should minimize the length of the blind afferent loop left at the time of initial RYGB to prevent candy cane Roux syndrome.

Endomina (Endo Tools Therapeutics, Gosselies, Belgium) is a CE marked device that may be attached to an endoscope inside the body and allows remote actuation of the device during a peroral intervention. It offers the possibilities of making transoral full thickness tissue apposition and may allow performing, via a transoral route, large plications with tight serosa to serosa apposition.


Description:

Surgery is currently the only effective treatment for morbid obesity and can be divided into restrictive surgeries (Lap Band and Sleeve gastrectomy), malabsorptive surgeries (Biliary pancreatic deviation and duodenal switch) or a combination of both (RYGBP).

This latter technique is the most common and most effective surgical procedure performed worldwide and has been processed to be an effective treatment of morbid obesity and its complications, achieving excess weight loss of 65 to 80 %; 1-2 years after surgery (1,2).

Morbidity after RYGB includes the candy cane syndrome or afferent loop syndrome. Candy cane Roux syndrome in patients who have undergone RYGB refers to an excessively long blind afferent Roux limb at the gastrojejunostomy causing postprandial pain often relieved by vomiting. It is believed that the blind afferent limb ("candy cane") acts as an obstructed loop when filled with food (often preferentially), and the distention of the loop causes pain until the food either spills into the Roux limb or is vomited back out (3).

Patients have been reported presenting as early as three months and as late as 11 years after their initial RYGB, typically with symptoms of postprandial epigastric pain, nausea, vomiting, and reflux or food regurgitation (4). The diagnosis is confirmed by upper gastrointestinal contrast studies or endoscopy. On upper gastrointestinal series, the afferent limb fills before contrast spills into the Roux limb. On upper endoscopy, the afferent limb is usually the most direct outlet of the gastrojejunostomy (3).

The treatment is revision bariatric surgery, most commonly laparoscopic resection of the afferent limb, which ranged in length from 3 to 22 cm in one study (mean of 7.6 cm) (3). Symptoms resolve after revision surgery in most patients. Surgeons should minimize the length of the blind afferent loop left at the time of initial RYGB to prevent candy cane Roux syndrome.

Endomina (Endo Tools Therapeutics, Gosselies, Belgium) is a CE marked device that may be attached to an endoscope inside the body and allows remote actuation of the device during a peroral intervention. It offers the possibilities of making transoral full thickness tissue apposition and may allow performing, via a transoral route, large plications with tight serosa to serosa apposition.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date March 3, 2020
Est. primary completion date March 3, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Proven Candy cane syndrome by barium swallow

2. Age between 18-65 years;

3. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;

4. Must be able to understand and be willing to provide written informed consent;

5. Must live within 75 km of the treatment site;

6. Had followed the bariatric multidisciplinary workup (blood analyses, dietician, psychologist and doctor appointments).

Exclusion Criteria:

1. Achalasia and any other esophageal motility disorders;

2. Severe esophagitis;

3. Gastro-duodenal ulcer;

4. Severe renal, hepatic, pulmonary disease or cancer;

5. GI stenosis or obstruction;

6. Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;

7. Anticoagulant therapy;

8. Impending gastric surgery 60 days post intervention;

9. Currently participating in other study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Endomina
The jejunum between the two loops is sutered with Endomina and cut 15 days later.

Locations

Country Name City State
Belgium CUB Hopital erasme Anderlecht
Belgium Gastroenterology Department Erasme Hospital Brussels

Sponsors (1)

Lead Sponsor Collaborator
Erasme University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Characterisation of safety by measurement of the incidence of all adverse device effects (ADE) Incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or the device.
Definitions are combined from EN ISO 14155:2011 and MEDDEV 2.7/3 rev 3 (May 2015).
6 months
Secondary Efficacy of the device: Dakkak and Bennett dysphagia score scoring using the Dakkak and Bennett dysphagia score 0 = no dysphagia; 4= aphagia Total scale will be reported 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04517591 - Reducing Sedentary Time in Bariatric: The Take a STAND for Health Study N/A
Active, not recruiting NCT04433338 - The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery N/A
Completed NCT05854875 - Diabetes Remission After RYGBP and RYGBP With Fundus Resection N/A
Recruiting NCT06460233 - Blood Pressure Changes After Bariatric Surgery
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Withdrawn NCT04771247 - Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy N/A
Not yet recruiting NCT03203161 - Registry on Obesity Surgery in Adolescents
Enrolling by invitation NCT02552433 - Complications in Body Contouring Surgery
Completed NCT02525016 - Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery Phase 3
Recruiting NCT01984762 - Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus. N/A
Not yet recruiting NCT01652105 - Randomized Trial of Preoperative Diets Before Bariatric Surgery N/A
Completed NCT00989157 - Effects of Gastric Bypass on Blood Levels of Duloxetine Phase 3
Completed NCT03609632 - Understanding Hypoglycaemia After Bariatric Surgery N/A
Completed NCT05454696 - Online Clinic Pilates Exercises in Patients Undergoing Bariatric Surgery N/A
Completed NCT04040647 - Tolerance of Early Postoperative Mobilization and Ambulation
Recruiting NCT04297306 - Virtual Reality Exercise Gaming in Patients Awaiting Bariatric Surgery N/A
Recruiting NCT05428618 - Mobile Application for Bariatric Surgery Patients N/A
Not yet recruiting NCT03900481 - Use of an Endoluminal-suturing Device for Endoscopic Gastric Reduction as an Aid for Class I Obesity, or Class II Obesity Without Comorbidity N/A
Not yet recruiting NCT03975244 - Semi-supervised Exercise Program Before Bariatric Surgery N/A
Recruiting NCT06170749 - Prediction Model for Anemia After Bariatric Surgery